Month: June 2017

CMS Publishes 2016 Open Payments Data

The Centers for Medicare & Medicaid Services (CMS) published today the Open Payments data reported earlier this year by applicable drug, device, biologic and medical supply manufacturers and group purchasing organizations (GPOs) related to payments and transfers of value to physicians and teaching institutions, and ownership or investment interests held by […]

Maine Enacts Gift Ban Law

Yesterday, An Act To Prohibit Certain Gifts to Health Care Practitioners became law in Maine without the signature of the Governor. 32 MRSA § 13759 prohibits licensed pharmaceutical and medical device manufacturers and wholesalers from providing a gift to a practitioner. Exceptions include: noncash items of minimal value that directly benefit the practitioner’s patients, […]

Nevada Enacts Transparency Bill Targeting Diabetes Drug Price Increases, Sales Representatives, PBMs, Nonprofit Organizations

As we discussed last week, Nevada’s Governor has signed into law SB 539, which provides sweeping transparency legislation related to several aspects of the pharmaceutical industry. Nevada joins several other states in adopting legislation aimed at addressing pharmaceutical price increases and other recent industry concerns. Diabetes Drug Pricing Reports February […]

Texas Becomes 50th State to Recognize Physician-Patient Relationship Established through Telemedicine

On May 27, Texas Governor Greg Abbott signed S.B. 1107 (the “Bill”), making Texas the last state in the nation to allow for the establishment of a physician-patient relationship through a virtual visit. The recently passed legislation eases the regulations surrounding the delivery of telemedicine services in Texas, and has […]

FDA Solicits Comments Regarding Two New Studies Related to Drug Promotion

The U.S. Food and Drug Administration (FDA) published two Federal Register notices today announcing its intent to study different aspects of drug promotion. In Docket No. FDA-2017-N-1315, the FDA solicited comments regarding its planned research titled, “Experimental Study on Risk Information Amount and Location in Direct-to-Consumer Print Ads.” The FDA explained that direct-to-consumer […]

Maryland Enacts Landmark Drug Price Gouging Legislation; Nevada Governor Considers Drug Pricing Bill

Maryland became the first state to enact legislation that outlaws “price gouging” in the generic drug market. H.B. 631, enacted on May 27, 2017 (the “Act”), has two components: (1) a prohibition on price gouging; and (2) a mechanism for reporting, investigating, and penalizing price gouging in the state’s Medicaid […]